

姓名:	李怡姿	填表日期: (YYYY/MM/DD)	2023.02.16	
單位:	急診部	現職職稱:	主治醫師	
Email:	ytle@vghtpe.gov.tw	連絡電話:	8#1490	
學歷:	國立陽明大學醫學系 國立陽明大學臨床醫學研究所博士			
重要經歷:	國立陽明交通大學醫學系教授 臺北榮民總醫院急診部主治醫師 臺北榮民總醫院內科部住院醫師 竹東榮民醫院主治醫師			
研究方向: (關鍵詞)	抗藥性, 革蘭氏陰性菌, 不動桿菌, 抗生素治療			
五年內 代表著作:	<ol style="list-style-type: none"> Chiang TT, Huang TW, Sun JR, Kuo SC, Cheng A, Liu CP, Liu YM, Yang YS, Chen TL, Lee YT*(corresponding author), Wang YC*. Biofilm formation is not an independent risk factor for mortality in patients with <i>Acinetobacter baumannii</i> bacteremia. <i>Front Cell Infect Microbiol</i>. 2022 Sep 16;12:964539. (SCI IF 6.073) Chiu YK, Yin T, Lee YT, Chen SJ, Wang YC, Ma KH. Proteomic Profiling of Outer Membrane Vesicles Released by <i>Escherichia coli</i> LPS Mutants Defective in Heptose Biosynthesis. <i>J Pers Med</i>. 2022 Aug 9;12(8):1301. (SCI IF 3.508) Wang YC, Lee YT, Matsuura K, Liu X, Cheng CM. Editorial: Detection Nanodevices for Infectious Diseases. <i>Front Bioeng Biotechnol</i>. 2022 Jun 29;10:962746. (SCI IF 6.064) Thuy TTD, Lu HF, Kuo PY, Lin WH, Lin TP, Lee YT, Duong TTT, Wang MC, Lee YH, Wen LL, Chen YC, Kao CY. Whole-genome-sequence-based characterization of an NDM-5-producing uropathogenic <i>Escherichia coli</i> EC1390. <i>BMC Microbiol</i>. 2022 Jun 6;22(1):150. (SCI IF 4.465) Lee CC, Lee YT, Wang CH, Chiu IM, Tsai W, Lin YR, Li CH, Hsu CW, Lai PF, Chen JH, Tsai JC, Tsai SH, How CK. Guidelines for COVID-19 Laboratory Testing for Emergency Departments From the New Diagnostic Technology Team of the Taiwan Society of Emergency Medicine. <i>J Acute Med</i>. 2022 Jun 1;12(2):45-52. Lee YT, Huang TW, Liu IF, Kuo SC, Yang YS, Lin PY, Liu CP, Liu YM, Chen TL, Wang FD, Wang YC. The prediction values of carbapenemase detection methods and carbapenem susceptibility testing for clinical outcomes of patients with <i>Acinetobacter</i> bacteremia under carbapenem treatment. <i>J Microbiol Immunol Infect</i>. 2022 Apr;55(2):257-265. (SCI IF 10.273) Hazam PK, Cheng CC, Hsieh CY, Lin WC, Hsu PH, Chen TL, Lee YT, Chen JY. Development of Bactericidal Peptides against Multidrug-Resistant <i>Acinetobacter baumannii</i> with Enhanced Stability and Low Toxicity. <i>Int J Mol Sci</i>. 2022 Feb 16;23(4):2191. (SCI IF 6.208) Wang YC, Lin SW, Wang IJ, Yang CY, Hong C, Sun JR, Feng PH, Lee MH, Shen CF, Lee YT*(corresponding author), Cheng CM*. Interleukin-6 Test Strip Combined With a Spectrum-Based Optical Reader for Early Recognition of COVID-19 Patients With Risk of Respiratory Failure. <i>Front Bioeng Biotechnol</i>. 2022 Feb 15;10:796996. (SCI IF 6.064) Huang SW, Sun MT, Lee WS, Su YS, Lee YT, Chiang MH, Wang YC, Yang YS, Tzeng SC, Huang YM, Lin FH. Cancer as an infectious disease: A different treatment alternative using a combination of tigecycline and pyrvinium pamoate - An example of breast cancer. <i>J Microbiol Immunol Infect</i>. 2022 Feb;55(1):51-59. (SCI IF 10.273) Chen CH, Tsao YT, Yeh PT, Liao YH, Lee YT, Liao WT, Wang YC, Shen CF, Cheng CM. Detection of Micro-organisms in Body Fluids via MTT-PMS Assay. <i>Diagnostics (Basel)</i>. 2021 Dec 27;12(1):46. (SCI IF 3.992) 			

11. Yang YS, Jeng WY, **Lee YT**, Hsu CJ, Chou YC, Kuo SC, Chen CC, Hsu WJ, The Action Study Group, Chen HY, Sun JR. Ser253Leu substitution in PmrB contributes to colistin resistance in clinical *Acinetobacter nosocomialis*. *Emerg Microbes Infect.* 2021 Dec;10(1):1873-1880. **(SCI IF 19.568)**
12. Liao PH, Kao CC, How CK, Yang YS, Chen MC, Hung-Tsang Yen D, **Lee YT***. Initial white blood cell count and revised Baux score predict subsequent bloodstream infection in burn patients: A retrospective analysis of severe burn patients from the Formosa color dust explosion of 2015. *J Formos Med Assoc.* 2021 Sep;120(9):1719-1728. **(SCI IF 3.282)**
13. Huang SW, Yeh FC, Ji YR, Su YF, Su YS, Chiang MH, Tzeng SC, Fu CY, Cheng A, Wang YC*, **Lee YT***. Chitosan-based hydrogels to treat hydrofluoric acid burns and prevent infection. *Drug Deliv Transl Res.* 2021 Aug;11(4):1532-1544. **(SCI IF 5.671)**
14. Feng JY, **Lee YT**, Pan SW, Yang KY, Chen YM, Yen DH, Li SY, Wang FD. Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study. *Antimicrob Resist Infect Control.* 2021 Jul 30;10(1):111. **(SCI IF 4.887)**
15. Wang YC, Tsai YH, Shen CF, He MY, Fu YC, Sang CY, **Lee YT***, Cheng CM*. Turntable Paper-Based De-vice to Detect *Escherichia coli*. *Micromachines (Basel).* 2021 Feb 13;12(2):194. **(SCI IF 3.523)**
16. Dutta P, Lu YJ, Hsieh HY, Lee TY, **Lee YT**, Cheng CM, Fan YJ*. 2021 Feb. Detection of *Candida albicans* Using a Manufactured Electrochemical Sensor. *Micromachines (Basel).* 2021 Feb 8;12(2):166. **(SCI IF 3.523)**
17. Li LH, Yang YS, Sun JR, Huang TW, Huang WC, Chen FJ, Wang YC, Kuo TH, Kuo SC, Chen TL, **Lee YT***, ACTION study group. Clinical and molecular characterization of *Acinetobacter seifertii* in Taiwan. *J Antimicrob Chemother.* 2021 Jan 19;76(2):312-321. **(SCI IF 5.790)**
18. Wang YC, Huang SW, Chiang MH, Lee IM, Kuo SC, Yang YS, Chiu CH, Su YS, Chen TL, Wang FD, **Lee YT***. In vitro and in vivo activities of imipenem combined with BLI-489 against class D β -lactamase-producing *Acinetobacter baumannii*. *J Antimicrob Chemother.* 2021 Jan 19;76(2):451-459. **(SCI IF 5.790)**
19. Cheng A, Sun HY, Tsai YT, Lu PL, Lee SS, **Lee YT**, Wang YC, Liu PY, Chien JY, Hsueh PR, Chang SY, Wu UI, Sheng WH, Chen YC, Chang SC*. 2021 Jan. Longitudinal non-cystic fibrosis trends of pulmonary *Mycobacterium abscessus* disease from 2010 to 2017: spread of the "globally successful clone" in Asia. *ERJ Open Res.* 2021 Jan 18;7(1):00191-2020.
20. Wang TY#, **Lee YT#**, Chen HY, Ko CH, Hong CT, Wen JW, Yen TH*, Cheng CM*. 2020 Dec. A Paper-Based Analytical Device for Analysis of Paraquat in Urine and Its Validation with Optical-Based Approaches. *Diagnostics (Basel).* 2020 Dec 22;11(1):E6. **(SCI IF 3.706)**
21. Chen YJ, He GC, Cheng JF, **Lee YT**, Hung YH, Chen WH, Huang YT, Liu PY*. 2020 Dec. Comparative genomics reveals insights into characterization and distribution of quorum sensing-related genes in *Shewanella* algae from marine environment and clinical sources. *Comp Immunol Microbiol Infect Dis.* 2020 Dec;73:101545. **(SCI IF 2.268)**
22. Chiu CH, **Lee YT**, Lin YC, Kuo SC, Yang YS, Wang YC, Liu YH, Lin JC, Chang FY, Chen TL*. 2020 Dec. Bacterial membrane vesicles from *Acinetobacter baumannii* induced by ceftazidime are more virulent than those induced by imipenem. *Virulence.* 2020 Dec;11(1):145-158. **(SCI IF 5.882)**
23. **Lee YT**, Chen HY, Yang YS, Chou YC, Chang TY, Hsu WJ, Lin IC; ACTION Study Group, Sun JR*. 2020 Nov. AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant *Acinetobacter nosocomialis*. *Front Microbiol.* 2020 Nov 2;11:584789. **(SCI IF 5.640)**
24. Kang FY, How CK, Wang YC, Cheng A, Yang YS, Kuo SC, Liu CP, Liu YM, Chen TL, **Lee YT***. 2020 Sep. Influence of severity of infection on the effect of appropriate antimicrobial therapy for *Acinetobacter baumannii* bacteremic pneumonia. *Antimicrob Resist Infect Control.* 2020 Sep 29;9(1):160. **(SCI IF 4.887)**
25. Wang YC#, **Lee YT#**, Yang T, Sun JR, Shen CF*, Cheng CM*. 2020 Aug. Current diagnostic tools for coronaviruses-From laboratory diagnosis to POC diagnosis for COVID-19. *Bioeng Transl Med.* 2020 Aug 13;5(3):e10177. **(SCI IF 10.711)**
26. **Lee YT**, Sun JR, Wang YC, Chiu CH, Kuo SC, Chen TL; ACTION Study Group, Yang YS*. 2020 Apr. Multi-centre study of risk factors for mortality in patients with *Acinetobacter* bacteraemia receiving colistin treatment. *Int J Antimicrob Agents.* 2020 Apr 9:105956. **(SCI IF 15.441)**

27. Chiang MH, Yang YS, Sun JR, Wang YC, Kuo SC, **Lee YT**, Chuang YP, Chen TL*. 2020 Mar. Confronting Tigecycline-Resistant *Acinetobacter baumannii* via Immunization Against Conserved Resistance Determinants. *Front Microbiol.* 2020 Mar 31;11:536. **(SCI IF 5.640)**
28. Chang YY, Yang YS, Wu SL, Wang YC, Chen TL; ACTION study group, **Lee YT***. 2020 Mar. Comparison of Cefepime/Cefpirome and Carbapenem Therapy for *Acinetobacter* Bloodstream Infection: A Multicentre Study. *Antimicrob Agents Chemother.* 2020 Mar 16. pii: AAC.02392-19. **(SCI IF 5.191)**
29. Wang YC, Ku WW, Yang YS, Kao CC, Kang FY, Kuo SC, Chiu CH, Chen TL, Wang FD, **Lee YT***. 2020 Jan. Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in *Acinetobacter baumannii* Bacteremia? *J Clin Med.* 2020 Jan 6;9(1). pii: E153. **(SCI IF 4.241)**
30. Liu CP, Chiang TT, Liu YM, Kuo SC, Yang YS, **Lee YT***, Chen TL, Shih SC; ACTION Study Group. 2019 Dec. A multicenter study on clinical characteristics of *Acinetobacter* bacteremia in patients with liver cirrhosis. *J Microbiol Immunol Infect.* 2019 Dec;52(6):956-965. **(SCI IF 10.273)**
31. Kao CC, Yen DH, **Lee YT***. 2019 Jul. Hiccups as the only symptom of acute myocardial infarction. *Am J Emerg Med.* 2019 Jul;37(7):1396.e1-1396.e3. **(SCI IF 2.469)**
32. Liu YH, Kuo SC, Yao BY, Fang ZS, **Lee YT**, Chang YC, Chen TL, Hu CJ. 2018 Dec. Colistin nanoparticle assembly by coacervate complexation with polyanionic peptides for treating drug-resistant gram-negative bacteria. *Acta Biomater.* 2018 Dec;82:133-142. **(SCI IF 8.947)**
33. Chen CT, Wang YC, Kuo SC, Shih FH, Chen TL, How CK, Yang YS, **Lee YT***. Community-acquired blood-stream infections caused by *Acinetobacter baumannii*: A matched case-control study. *J Microbiol Immunol Infect.* 2018 Oct;51(5):629-635. **(SCI IF 10.273)**
34. Wang YC, Huang TW, Yang YS, Kuo SC, Chen CT, Liu CP, Liu YM, Chen TL, Chang FY, Wu SH, How CK, **Lee YT***. 2018 May. Biofilm formation is not associated with worse outcome in *Acinetobacter baumannii* bacteraemic pneumonia. *Sci Rep.* 2018 May 8;8(1):7289. **(SCI IF 4.379)**
35. Lee Y, **Lee YT**, Wang YC, Chen CT, Sun JR, Liu CP, Liu YM, Kuo SC, Chiu CH, Yang YS*, Lin JC*, Chen TL. 2018 Jun. Risk of Mortality of Catheter-Related Bloodstream Infections Caused by *Acinetobacter* Species: Is Early Removal of the Catheters Associated With a Better Survival Outcome? *J Intensive Care Med.* 2018 Jun;33(6):361-369. **(SCI IF 3.510)**

研究室成員： 莊明芬、王思穎、林家加、許惠雯、馬若宇